RenovoRx Reports Revenue Growth and Trial Progress

Renovorx, Inc. ( (RNXT) ) has released its Q2 earnings. Here is a breakdown of the information Renovorx, Inc. presented to its investors.

RenovoRx, Inc. is a life sciences company focused on developing targeted oncology therapies and commercializing the RenovoCath device, which is FDA-cleared for local drug delivery. The company operates within the medical device and biotechnology sectors, emphasizing innovative solutions for cancer treatment.

In its latest earnings report, RenovoRx announced a significant commercial revenue growth in the second quarter of 2025, driven by its RenovoCath device. The company also shared positive news from its ongoing Phase III TIGeR-PaC trial, with an independent committee recommending the continuation of the study based on interim data.

The company reported over $400,000 in revenue for the second quarter of 2025, highlighting the demand for its RenovoCath device. The commercialization efforts have expanded to thirteen cancer centers, with repeat orders indicating strong market acceptance. Additionally, RenovoRx’s cash position stood at $12.3 million, supporting its ongoing projects and trial completions. The company also announced the hiring of a new Senior Director of Sales and Market Development to further boost its market presence.

RenovoRx’s ongoing Phase III TIGeR-PaC trial is evaluating its drug-device combination for treating locally advanced pancreatic cancer. The trial has reached significant milestones, with 95 patients randomized and 61 events recorded. The company plans to complete enrollment by the end of this year or early next year.

Looking ahead, RenovoRx aims to continue its commercialization momentum and expand its market reach. The company’s management remains optimistic about the potential of its RenovoCath device and ongoing trials, positioning itself for long-term growth in the targeted oncology therapy market.